Supramolecular complex sacubitril/valsartan - the first representative of a new class of drugs for the treatment of chronic heart failure
The average prevalence of сhronic heart failure in the adult population, according to the statistics of different countries, ranges from 1.5 % to 5.5 % and therefore the study of this problem and of finding new approaches to the treatment of сhronic heart failure is also still relevant at present....
Main Authors: | T. V. Ashcheulova, K. M. Kompaniiets, N. M. Herasimchuk |
---|---|
Format: | Article |
Language: | English |
Published: |
Zaporozhye State Medical University
2019-12-01
|
Series: | Patologìâ |
Subjects: | |
Online Access: | http://pat.zsmu.edu.ua/article/view/188964/189447 |
Similar Items
-
Spotlight on valsartan–sacubitril fixed-dose combination for heart failure: the evidence to date
by: Vilela-Martin JF
Published: (2016-05-01) -
Renin profiling predicts neurohormonal response to sacubitril/valsartan
by: Giuseppe Vergaro, et al.
Published: (2021-02-01) -
EFFECTS OF SACUBITRIL/VALSARTAN ON THE ARTERIAL STIFFNESS AND LEFT VENTRICULAR-ARTERIAL COUPLING IN PATIENTS WITH HEART FAILURE WITH REDUCED EJECTION FRACTION
by: Zh. D. Kobalava, et al.
Published: (2018-05-01) -
Sacubitril/Valsartan as a Therapeutic Tool Across the Range of Heart Failure Phenotypes and Ejection Fraction Spectrum
by: Giovanna Gallo, et al.
Published: (2021-08-01) -
Effects of Sacubitril/Valsartan on Serum Lipids in Heart Failure With Preserved Ejection Fraction
by: Senthil Selvaraj, et al.
Published: (2021-09-01)